1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

YIHCF
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.US flagOther OTC
0.55
USD
- -
- -
643.13MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
0.49
1.03
1.04
1.77
2.78
7
2.66
1.04
4.26
7.15
4.23
Basic EPS, GAAP
0.15
0.4
0.42
0.72
1.04
2.16
0.95
-0.67
0.09
2.26
0.55
Free Cash Flow per Basic Share
0.1
-0.05
0.25
0.33
-0.42
0.14
-0.7
-1.41
0.96
1.23
-1.24
Dividend per Share
- -
- -
0.08
0.35
0.35
0.81
0.25
- -
- -
- -
- -
Book Value per Share
0.19
0.67
0.5
0.5
0.5
0.5
1
1
3.35
5.49
6.03
Tangible Book Value per Share
0.21
3.07
2.73
2.89
3.43
4.18
2.63
3.04
3.45
6.1
6.82
Basic Weighted Avg Shares
901
671
902
904
904
889
881
880
880
880
880
Sales/Revenue/Turnover
441
693
942
1,602
2,510
6,224
2,348
914
3,745
6,295
3,724
Operating Margin (%)
41.77
47.73
44.78
47.65
43.16
39.3
18.86
-48.24
31.46
45.72
21.13
Depreciation Expense
32
26
27
44
61
86
123
260
377
391
396
Net Income, GAAP
135
266
381
647
943
1,919
839
-588
77
1,993
483
Effective Tax Rate (%)
17.03
15.56
16
16.28
18.24
15.95
17.12
- -
- -
12.74
16.37
Profit Margin (%)
30.7
38.35
40.42
40.4
37.54
30.83
35.75
-64.31
2.05
31.66
12.96
Working Capital
32
1,539
1,617
1,428
973
3,019
-897
819
73
1,721
2,193
LT Debt
145
90
20
10
- -
2,903
190
3,145
692
289
900
Total Equity
277
2,143
2,458
3,061
3,679
4,623
5,104
6,021
6,070
7,936
8,508
Return on Invested Capital (%)
- -
18.21
14.3
21.95
25.11
34.96
4.57
- -
- -
24.03
6.07
Return on Capital (%)
- -
46.57
65.18
106.11
133.55
94.5
26.76
- -
- -
32.36
7.53
Return on Common Equity (%)
- -
85.52
84.44
143.35
208.52
425.98
126.35
-66.78
4
51.27
9.52

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
82.51%
13.43%
7.22%
Free Cash Flow
-214.04%
-170.09%
-201.35%
Net Income, GAAP
244.5%
417.23%
-75.78%
Sales/Revenue/Turnover
58.15%
42.74%
-40.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
3,745
2023
- -
- -
- -
- -
6,295
2024
- -
- -
- -
- -
3,724

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
0.09
2023
- -
- -
- -
- -
2.26
2024
- -
- -
- -
- -
0.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Juncai Jiang
Full Time Employees
4,618
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
No. 38, Binjiang Road Yichang People's Republic of China
IPO Date
Sep 15, 2021
Website
cj.hec.cn
Similar Companies
MediPharm Labs Corp. (LABS.TO)
IM Cannabis Corp. (IMCC.CN)
Earth Science Tech, Inc. (ETST)
Next Generation Management Corp. (NGMC)
Levitee Labs Inc. (LVT.CN)
Aurora Cannabis Inc. (ACB.TO)
Business
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. engages in the development, manufacturing and sale of pharmaceutical products focused on anti-virus, endocrine and metabolic, and cardiovascular therapeutic areas in the People's Republic of China. The company manufactures and sells active pharmaceutical ingredients and finished drugs including flagship antiviral products such as Kewei (oseltamivir phosphate granules and capsules), Ertongshu, Xinhaining and Xining; cardiovascular and metabolic offerings such as Oumeining (telmisartan), Benzbromarone, Amlodipine Besylate and Cetirizine Hydrochloride; innovative pipeline drugs including Emitasvir Phosphate capsules for hepatitis C, Encofosbuvir Tablets approved in March 2025 as a pan-genotypic chronic hepatitis C treatment, Netanasvir Phosphate Capsules approved in February 2025, insulin series products and the SGLT-2 inhibitor Olorigliflozin submitted for type 2 diabetes treatment; as well as medical devices, biotechnology research and marketing consulting services. It distributes products to hospitals and medical institutions via an extensive network of distributors and engages in centralized bulk procurement with 12 chemical generic drugs; founded in 2001 and headquartered at No. 38 Binjiang Road in Yichang, China, it operates as a subsidiary of Guangdong HEC Technology Holding Co., Ltd. with approximately 4,861 employees. In 2025, Sunshine Lake Pharma Co., Ltd. completed the acquisition of the remaining 48.6% stake for HKD 8.3 billion through a merger by absorption finalized on August 7, following shareholder approvals in July 2025, NDRC approval and Stock Exchange delisting clearance, resulting in the company's privatization and delisting from the Hong Kong Stock Exchange.